Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Champions Oncology Inc (CSBR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Champions Oncology's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
5.030 -0.010    -0.20%
18/04 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 1,205
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 4.960 - 5.100
Champions Oncology 5.030 -0.010 -0.20%

CSBR Recent Sentiments

 
This page contains information on users’ sentiments for the Champions Oncology Inc stock, which are displayed both on charts of different periods of time and on a detailed table.
Start Date Username Call Open Rate End Date Chg. %
Jun 26, 2023 Luca Gianoli   6.100 Nov 30, 2023 @ 5.310 -12.95%
Dec 15, 2022 Robbert Kuipers   5.900 Jan 06, 2023 @ 4.290 -27.29%
May 23, 2022 ROMAN MIGUEL   7.250 Jun 17, 2022 @ 7.570 +4.41%
Mar 03, 2022 ROMAN MIGUEL   8.300 Mar 25, 2022 @ 8.500 +2.41%
Dec 23, 2021 Gianni Gioda   7.780 Jan 14, 2022 @ 7.860 +1.03%
Nov 04, 2021 kc monk   10.245 Nov 26, 2021 @ 9.230 +9.91%
Nov 04, 2021 kc monk   10.245 Nov 26, 2021 @ 9.230 +9.91%
Nov 04, 2021 kc monk   10.245 Nov 26, 2021 @ 9.230 +9.91%
Jun 28, 2021 Robbert Kuipers   10.450 Jul 05, 2021 @ 9.420 -9.86%
Jun 28, 2021 Robbert Kuipers   10.500 Jul 23, 2021 @ 10.460 -0.38%
Jun 28, 2021 Robbert Kuipers   10.500 Jun 28, 2021 @ 10.500 0.00%
Mar 18, 2021 Giuseppe Denis...   13.500 Mar 30, 2021 @ 11.690 -13.41%
Jan 12, 2021 davide lombardi   10.880 Feb 05, 2021 @ 11.970 +10.02%
Aug 20, 2020 Andreas Schatz   9.000 Sep 11, 2020 @ 7.320 -18.67%
Jul 16, 2020 Andrejs Mernaks   9.230 Jul 22, 2020 @ 9.330 +1.08%
Jun 26, 2020 Vadym Shvets   9.240 Jul 17, 2020 @ 9.250 +0.11%
May 15, 2020 Master Trader   9.500 Jun 05, 2020 @ 9.020 +5.05%
Mar 13, 2020 Valentin Viktorovich   5.810 Apr 03, 2020 @ 6.750 +16.18%
Jan 27, 2020 Weidong Jia   8.040 Feb 21, 2020 @ 7.000 +12.94%
Jan 22, 2020 Jan Kaluta   8.060 Feb 14, 2020 @ 7.240 -10.17%
Jan 13, 2020 Riccardo Dazzi   7.975 Feb 07, 2020 @ 7.250 -9.09%
Jan 07, 2020 Agustín García   7.900 Jan 31, 2020 @ 7.590 -3.92%
Jan 06, 2020 Riccardo Taliano   7.950 Jan 31, 2020 @ 7.590 +4.53%
Dec 17, 2019 Andrea Locatelli   7.380 Jan 10, 2020 @ 8.170 +10.70%
Dec 16, 2019 Davide Preto   7.630 Jan 10, 2020 @ 8.170 +7.08%
Dec 06, 2019 Mario Rossi   7.520 Dec 27, 2019 @ 7.710 +2.53%
Sep 17, 2019 keras kuip   5.760 Oct 11, 2019 @ 5.910 +2.60%
Sep 10, 2019 keras kuip   6.360 Sep 17, 2019 @ 5.760 -9.43%
Sep 06, 2019 keras kuip   6.470 Sep 10, 2019 @ 6.360 -1.70%
Jul 24, 2019 Davide Preto   7.040 Aug 16, 2019 @ 6.180 +12.22%
Apr 18, 2019 Davide Preto   7.610 May 10, 2019 @ 8.660 +13.80%
Mar 14, 2019 Davide Preto   10.436 Apr 05, 2019 @ 9.200 -11.84%
Feb 14, 2019 Marco Cisotto   9.900 Mar 16, 2019 @ 10.130 +2.32%
Nov 06, 2018 Parth Korde   14.320 Dec 06, 2018 @ 2.490 +82.61%
Oct 02, 2018 John Janiszewski   13.605 Nov 01, 2018 @ 2.490 +81.70%
Oct 02, 2018 Dragan Milanovic   14.551 Nov 01, 2018 @ 2.490 -82.89%
Oct 01, 2018 Yossi Peretz   14.050 Oct 31, 2018 @ 2.490 -82.28%
Sep 28, 2018 Marco Cisotto   17.576 Oct 28, 2018 @ 2.490 -85.83%
Sep 28, 2018 Parth Korde   16.960 Oct 28, 2018 @ 2.490 -85.32%
Sep 28, 2018 Julio Rarhez   16.900 Oct 28, 2018 @ 2.490 -85.27%
Sep 27, 2018 jm landaluce   16.810 Sep 28, 2018 @ 17.290 +2.86%
Sep 27, 2018 Szabolcs Heizer   16.535 Oct 27, 2018 @ 2.490 -84.94%
Sep 21, 2018 Ignacio Lasalde   12.182 Oct 21, 2018 @ 2.490 +79.56%
Sep 20, 2018 Jan Kaluta   12.760 Oct 20, 2018 @ 2.490 -80.49%
Sep 20, 2018 Andre86   14.530 Oct 20, 2018 @ 2.490 -82.86%
Sep 18, 2018 Santi M Moriel   12.819 Oct 18, 2018 @ 2.490 -80.58%
Sep 18, 2018 Simone Daniele...   12.298 Oct 18, 2018 @ 2.490 +79.75%
Sep 14, 2018 Rambabu Verma   10.320 Oct 14, 2018 @ 2.490 -75.87%
Sep 05, 2018 Luca Mancino   8.405 Sep 21, 2018 @ 13.210 +57.17%
Sep 04, 2018 Davide Gheno   8.660 Oct 04, 2018 @ 2.490 -71.25%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CSBR Comments

Write your thoughts about Champions Oncology Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email